Close
Explore more Centres, Projects and Groups
Home
Welcome Banner
Banner
Praziquantel in Preschool Children (PIP trial)

Praziquantel in Preschool Children (PIP trial)

The Praziquantel in Preschoolers trial (PIP) aims to find the right treatment dose of praziquantel for preschool children living with intestinal schistosomiasis in Uganda.

Bottom Content
Logo List Links
Intro Blocks List
About us

Intestinal schistosomiasis is a complex parasitic disease that affects millions of children in worldwide. With only one drug to treat it (praziquantel), there is still no optimal dosing for children under 5 years of age.

Donations
Twitter Embedded Code
Facebook Embedded Code
About
Praziquantel in Preschool Children (PIP trial) 2 columns
Praziquantel in Preschool Children (PIP trial) about
Paragraph

Intestinal schistosomiasis is a complex parasitic disease that affects millions of children worldwide. With only one drug to treat it (praziquantel), there is still no optimal dosing for children under 5 years of age.

The PIP trial (Praziquantel in Preschoolers) is a five year randomised controlled trial investigating different doses and treatment intervals of praziquantel given to children under five years of age. It will also explore the role of intestinal pathology on the pharmacokinetics and pharmacodynamics of praziquantel and its role in drug efficacy.

Collaborating partners

Center for international health research lifespan
MRC Uganda
Uganda logo
University of Liverpool
Brown University-Center for International Health Research  LSHTM-MRC Unit Vector Control Division
Uganda Ministry of Health
University of Liverpool

Funder

NIH

National Institutes of Health (NIH)

Who we are

The PIP Trial is funded by the National Institutes of Health in the USA. It brings together LSHTM, Brown University, the LSHTM MRC unit in Uganda and the Vector Control Division from the Ministry of Health in Uganda.

Profiles
Profiles List
Principal Investigators
Principal investigator (UK)

Jennifer Friedman

Principal investigator (US)

Patrice Mawa

Principal investigator (Uganda)
Trial Statistician
Study Manager

Andrew Edielu

Co-investigators

Narcis Kabatereine

Edridah Muheki

Alison Elliott

Hannah Wu

Publications
Scientific Papers
Publications List
The praziquantel in preschoolers (PIP) trial: study protocol for a phase II PK/PD-driven randomised controlled trial of praziquantel in children under 4 years of age
Webb EL, Edielu A, Wu HW, Kabatereine NB, Tukahebwa EM, Mubangizi A, Adriko M, Elliott AM, Hope WW, Mawa PA, Friedman JF, Bustinduy AL
2021
PubMed. 2021 Sep 6;22(1):601. doi: 10.1186/s13063-021-05558-1.
One hundred years of neglect in paediatric schistosomiasis
Bustinduy, AL; Wright, S; Joekes, EC; Kabatereine, NB; Reinhard-Rupp, J; King, CH; Stothard, JR
2017
Parasitology. pp. 1-11. ISSN 0031-1820 DOI: https://doi.org/10.1017/S0031182017000014
Paediatric and maternal schistosomiasis: shifting the paradigms
Bustinduy, AL; Stothard, JR; Friedman, JF
2017
British medical bulletin, 123 (1). pp. 115-125. ISSN 0007-1420 DOI: https://doi.org/10.1093/bmb/ldx028
Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy
Bustinduy, Amaya; Waterhouse, David; Sousa-Figueiredo, Jose C; Roberts, Stephen A.; Atuhaire, Aaron; Van Dam, Govert J.; Corstjens, Paul L. A. M.; Scott, Janet T.; Stanton, Michelle C.; Kabatereine, Narcis B.; Ward, Stephen; Hope, William W.; Stothard, J.Russell
2016
MBio. ISSN 2150-7511 DOI: https://doi.org/10.1128/mBio.00227-16
Expanding Praziquantel (PZQ) Access beyond Mass Drug Administration Programs: Paving a Way Forward for a Pediatric PZQ Formulation for Schistosomiasis.
Bustinduy AL; Friedman JF; Kjetland EF; Ezeamama AE; Kabatereine NB; Stothard JR; King CH
2016
PLoS neglected tropical diseases
Updates
BILHIV Updates
Updates List
Our team present baseline data at the American Society of Tropical Medicine and Hygiene (ASTMH) in Seattle

Our wonderful team presented baseline data at the American Society of Tropical Medicine and Hygiene (ASTMH) in Seattle.

Initial baseline results of the PIP trial were presented at the American Society of Tropical Medicine and Hygiene in Seattle.

Sophie Pach presented the baseline ultrasound findings of the PIP trial. Results highlighted incipient fibrosis in preschool children.

Suzanne presented baseline results on morbidity markers in preschool children with intestinal schistosomiasis. Anaemia was found to be associated with high intensity S.mansoni infection.

Andrew Edielu presented baseline results on proxy markers of gut inflammation and blood in stool- both biomarkers were associated with S.mansoni infection.

Congratulations to Andrew Edielu, Sophie Pach and Suzanne Colt.

Sophie Pach presenting at HEIC
Sophie Pach
Andrew Edielu presenting at HEIC
Andrew Edielu
Suzanne Colt presenting at HEIC
Suzanne Colt
PIP team- Sophie Pach, Andrew Edielu, Suzanne Colt, Jennifer Friedman and Amaya Bustinduy
PIP team - Sophie Pach, Andrew Edielu, Suzanne Colt, Jennifer Friedman and Amaya Bustinduy
We have started recruiting at our research camp

We have started recruiting at our research camp in Lake Albert on April 16, 2021. Excellent team efforts!

Recruitment of first patients for the PIP trial- April 2021
Recruitment of first patients for the PIP trial - April 2021. Photo from A. Bustinduy with consent from participants.
Recruitment of first patients for the PIP trial- April 2021

 

The Kabatereine Schistosomiasis Research Camp was officially inaugurated in April 2019